Web Date: April 23, 2012
AstraZeneca To Buy Ardea
AstraZeneca has struck a deal to buy the small-molecule biotechnology company Ardea Biosciences for $1.26 billion. The San Diego-based firm has three compounds in development—two that target gout and one in the oncology area.
Ardea’s most advanced candidate, lesinurad, is a selective inhibitor of URAT1, a transporter in kidney cells that regulates uric acid excretion from the body. Chronic hyperuricaemia, or abnormally elevated uric acid levels in the blood, is . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society